

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(original):** A method of diagnosing disease of bacterial or fungal origin in a subject, which method comprises the step of measuring the level of sTREM-1 in a biological sample obtained from said subject.
2. **(original):** The method of claim 1 wherein said step of measuring the level of sTREM-1 comprises the steps of:
 - (a) contacting said biological sample with a compound capable of binding sTREM-1;
 - (b) detecting the level of sTREM-1 present in the sample by observing the level of binding between said compound and sTREM-1.
3. **(currently amended):** The method of ~~claim 1 or~~ claim 2, comprising the further step of:
 - c) correlating the detected level of sTREM-1 with the presence or absence of disease of bacterial or fungal origin.
4. **(currently amended):** The method of claim 3 where said correlation is made by comparing the measured level of sTREM-1 in the sample with a mean level in a control population of individuals not having disease of bacterial or fungal origin, to indicate the presence or extent of disease of bacterial or fungal origin in said subject ~~the patient~~.
5. **(currently amended):** The method of ~~any one of claims 1 to 4~~ claim 1, further comprising the steps of measuring the level of sTREM-1 in a second or further sample from said subject ~~the patient~~, the first and second or further samples being obtained at

different times; and comparing the levels in the samples to indicate the progression or remission of the disease of bacterial or fungal origin.

6. **(currently amended):** The method of ~~any one of claims 1 to 5~~ claim 1 wherein said disease of bacterial or fungal origin is pneumonia.

7. **(currently amended):** The method of ~~any one of claims 1 to 5~~ claim 1 wherein said disease of bacterial or fungal origin is sepsis.

8. **(currently amended):** The method of ~~any one of claims 1 to 7~~ claim 1, wherein the sample is selected from the group consisting of whole blood, blood serum, blood plasma, urine and bronchoalveolar lavage fluid.

9. **(original):** The method of claim 6 wherein the sample is from bronchoalveolar lavage fluid.

10. **(original):** The method of claim 7 wherein the sample is from blood serum or blood plasma.

11. **(currently amended):** The method of ~~any one of claims 1 to 10~~ claim 1 wherein the sample is a human sample.

12. **(original):** A compound capable of binding sTREM-1 for use in the diagnosis, prognosis, monitoring of the treatment of disease of bacterial or fungal origin.

13. **(cancelled)**

14. **(original):** A method of identifying agonists or antagonists of sTREM-1, said method comprising comparing the level of binding in a sample containing said sTREM-1 and a compound capable of binding sTREM-1 in the presence and absence of a compound to be tested.

15. **(original):** An agonist or antagonist of sTREM-1 identified according to the method of claim 14.

16. (original): A kit comprising at least one compound capable of binding sTREM-1 and reagents for detecting binding of said compound to sTREM-1 for use in the diagnosis of disease of bacterial or fungal origin

17. (original): A kit comprising at least one compound capable of binding sTREM-1 and means for contacting said compound with a sample containing sTREM-1 for use in the diagnosis of disease of bacterial or fungal origin.

18. (currently amended): The method, ~~compound, use or kit of any of the preceding claims~~ of claim 2 wherein said compound specifically binds sTREM-1.

19. (currently amended): The method, ~~compound, use or kit of any of the preceding claims~~ of claim 2 wherein said compound capable of binding sTREM-1 is an antibody raised against all or part of the TREM-1 receptor.

20. (original): In a method of screening a patient for presence or susceptibility to disease, comprising performing a plurality of diagnostic tests on a tissue sample from the patient for a plurality of diseases, the improvement wherein one of the diagnostic tests comprises measuring the level of sTREM-1.

21. (cancelled)

22. (currently amended): The method of ~~any one of claims 1 to 11~~ claim 1 wherein the level of sTREM-1 is measured by an immunochemical technique.

23. (currently amended): The method of ~~any one of claims 1 to 10~~ claim 1 comprising the additional step of measuring the level of TREM-1-Ligand in one or more biological samples obtained from said subject.